Adaptimmune Therapeutics plc
ADAP
$0.0585
$0.00142.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -53.99% | 878.53% | 195.34% | 146.27% | 99.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.99% | 878.53% | 195.34% | 146.27% | 99.90% |
| Cost of Revenue | -12.25% | 5.50% | 17.88% | -35.23% | -19.97% |
| Gross Profit | -1,125.08% | 130.54% | 143.64% | 121.26% | 95.38% |
| SG&A Expenses | 39.43% | 38.23% | 46.80% | 9.17% | 0.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.54% | 16.13% | 27.23% | 18.13% | 19.86% |
| Operating Income | -120.29% | 70.23% | 52.81% | 65.38% | 33.87% |
| Income Before Tax | -132.50% | 59.14% | 40.25% | 53.06% | 19.14% |
| Income Tax Expenses | 242.66% | 193.05% | 167.66% | -58.91% | -59.86% |
| Earnings from Continuing Operations | -134.15% | 57.23% | 37.81% | 53.24% | 20.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.15% | 57.23% | 37.81% | 53.24% | 20.35% |
| EBIT | -120.29% | 70.23% | 52.81% | 65.38% | 33.87% |
| EBITDA | -144.86% | 74.66% | 58.44% | 73.68% | 40.69% |
| EPS Basic | -93.23% | 62.68% | 44.94% | 57.40% | 36.98% |
| Normalized Basic EPS | -98.42% | 73.32% | 57.99% | 68.43% | 49.05% |
| EPS Diluted | -83.11% | 55.93% | 35.70% | 51.29% | 31.61% |
| Normalized Diluted EPS | -95.54% | 72.76% | 57.22% | 67.63% | 48.32% |
| Average Basic Shares Outstanding | 8.62% | 16.40% | 25.62% | 32.42% | 40.35% |
| Average Diluted Shares Outstanding | 8.13% | 16.89% | 25.92% | 32.73% | 40.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |